Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and CNS Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PDE4B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PDE4B Recombinant Protein (Catalytic Domain & Full Length) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View PDE4B Products |
| Gene Delivery | PDE4B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PDE4B Products |
| Benchmark Ab | Anti-PDE4B (Recombinant Rabbit mAb) Positive control for detection and IP. |
View PDE4B Products |
| Validator | PDE4B siRNA Set (3 unique targets) For knockdown verification and specificity controls. |
View PDE4B Products |
| Related Target (Selectivity) | PDE4D Essential for subtype selectivity screening (avoid emesis liability). |
View PDE4D Products |
| Related Target (Dual Inhibition) | PDE3A Exploratory target for cardiopulmonary dual PDE3/4 inhibition strategies. |
View PDE3A Products |
| Related Target (Isoform Profiling) | PDE4A Isoform selectivity panel; off-target profiling. |
View PDE4A Products |
| Related Target (Family Completeness) | PDE4C Family-wide selectivity panel completeness. |
View PDE4C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subtype Selectivity (PDE4B vs PDE4D) | PDE4B & PDE4D Panel available: Human ortholog proteins with >95% purity, Sequence Verified. |
| Enzymatic Activity Preservation | Catalytic domain constructs expressed in HEK293 or Baculovirus. Endotoxin Controlled. |
| Cellular cAMP Accumulation Assay | Lentivirus for stable PDE4B overexpression; Validated siRNA for target engagement confirmation. |
| Mechanism Validation | Reference inhibitor standards; High-purity cAMP substrate. |
| Cross-species Translation | Human/Mouse/Rat ortholog proteins available with >95% purity for uniform screening. |
| False Positives in Phenotypic Screens | Valid siRNA sets for precise specificity checks. |
Live PDE4B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PDE4B therapeutics is intensifying, with major players shifting focus from pan-PDE4 inhibitors to highly selective PDE4B modulators. First-generation non-selective PDE4 inhibitors (apremilast, roflumilast) established anti-inflammatory proof-of-concept but suffer from dose-limiting emesis driven by PDE4D inhibition. The next wave targets subtype-selective small molecules for CNS indications (Huntington's disease, neuroinflammation), allosteric inhibitors, PROTAC degraders, and optimized topical formulations to achieve maximal anti-inflammatory efficacy with minimal systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Subtype-Selective Small Molecule | Pfizer, Biogen, Dermavant | Huntington's, Psoriasis, Neuroinflammation | Selectivity Assay (PDE4B vs PDE4D mutant vs WT proteins) |
| Allosteric Modulators | Boehringer Ingelheim, Tetra Therapeutics | IPF, COPD, Neuroinflammation | Conformational Binding Assay (Full-length native protein) |
| PROTAC / Degrader | Biotech Innovators, Academia | Severe Asthma, Psoriasis | Degradation Kinetics (Anti-PDE4B Abs) |
| Topical Inhibitor | Arcutis Biotherapeutics | Atopic Dermatitis, Psoriasis | Enzymatic Assay (Active PDE4B isoforms) |
| Pan-PDE4 Inhibitor (Next-Gen) | Arcutis, Viatris | Atopic Dermatitis, COPD | Enzymatic Inhibition Assay (High-purity catalytic domain) |
Target Identity & Key Facts
PDE4B (Phosphodiesterase 4B, UniProt Q07343) is a cAMP-specific phosphodiesterase. Its catalytic domain (PDEase) mediates cAMP hydrolysis. A known missense mutation (rs2227297, UniProt VAR_034373) has been documented. No direct interacting proteins are currently listed in the reference database. This information ensures accurate target engagement in assay development.